UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2021
Commission File Number 001-38810
STEALTH BIOTHERAPEUTICS CORP
(Translation of registrant’s name into English)
Stealth BioTherapeutics Corp
c/o Intertrust Corporate Services (Cayman) Limited
One Nexus Way, Camana Bay
Grand Cayman
KY1-9005 Cayman Islands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F ☒ FORM 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Annual General Meeting Results
On July 14, 2021, Stealth BioTherapeutics Corp (the “Company”) held its 2021 Annual General Meeting (the “AGM”). All of the resolutions duly proposed in the Notice of Annual General Meeting were approved at the AGM. The resolutions are described in the Company’s proxy statement for the AGM.
The voting results for each of the resolutions is set forth below.
| | | | | | | | | | | | | |
| | For | | | | Against | | Abstain | | |
Resolution 1 | | | | | | | | | | | | | |
Re-election of Francis W. Chen, Ph.D. as Class II Director | | | 491,909,799 | | | | | 2,376,300 | | 157,020 | | | |
| | | | | | | | | |
Re-election of Louis Lange, M.D., Ph.D. as Class II Director | | | 494,078,619 | | | | | 207,432 | | 157,068 | | | |
| | | | | | | | | |
Resolution 2 | | | | | | | | | | | | | |
Increase of Authorized Share Capital | | | 491,940,639 | | | | | 2,396,808 | | 105,672 | | | |
| | | | | | | | | |
Share Capital Increase
As a result of the shareholder vote, the Company’s authorized share capital was increased from US$360,000 divided into 1,200,000,000 Ordinary Shares of a nominal or par value of US$0.0003 each to US$480,000 divided into 1,600,000,000 Ordinary Shares of a nominal or par value of US$0.0003 each. A copy of the Amended and Restated Memorandum and Articles of Association of the Registrant, as amended, is attached hereto as an exhibit and incorporated herein by reference.
This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
1
EXHIBIT INDEX
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
STEALTH BIOTHERAPEUTICS CORP |
| |
By: | /s/ Irene P. McCarthy |
| Irene P. McCarthy |
| Chief Executive Officer |
|
Date: July 20, 2021 |
3
